PaxMedica
PaxMedica
PXMD
OTC
0.00
USD
0.00%
About
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19).
Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 8.7K |
| Three Month Average Volume | 564.1K |
| High Low | |
| Fifty-Two Week High | 10.26 USD |
| Fifty-Two Week Low | 0.2 USD |
| Fifty-Two Week High Date | 07 Nov 2023 |
| Fifty-Two Week Low Date | 10 Jul 2024 |
| Price and Volume | |
| Current Price | 0.21495 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.98% |
| Thirteen Week Relative Price Change | -39.18% |
| Twenty-Six Week Relative Price Change | -69.92% |
| Fifty-Two Week Relative Price Change | -97.76% |
| Year-to-Date Relative Price Change | -76.02% |
| Price Change | |
| One Day Price Change | 3.00% |
| Thirteen Week Price Change | -34.90% |
| Twenty-Six Week Price Change | -66.93% |
| Five Day Price Change | 1.87% |
| Fifty-Two Week Price Change | -97.19% |
| Year-to-Date Price Change | -71.61% |
| Month-to-Date Price Change | -10.44% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.45737 USD |
| Book Value Per Share (Most Recent Quarter) | 0.1594 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.45737 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.1594 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.74233 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -10.99939 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -11.18796 USD |
| Normalized (Last Fiscal Year) | -10.97197 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -10.99939 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -11.18796 USD |
| Including Extraordinary Items (Last Fiscal Year) | -10.99939 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -11.18796 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.63647 USD |
| Cash Per Share (Most Recent Quarter) | 0.21792 USD |
| Cash Flow Per Share (Last Fiscal Year) | -10.99936 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.25794 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 158.98% |
| Tangible Book Value (5 Year) | 315.91% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 90.35% |
| EPS Change (Trailing Twelve Months) | 59.73% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,626,890 |
| Net Debt (Last Fiscal Year) | -4,710,640 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -10,768,500 |
| Free Cash Flow (Trailing Twelve Months) | -10,853,620 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1,761 |
| Net Interest Coverage (Trailing Twelve Months) | -3,015 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -463.93% |
| Return on Assets (Trailing Twelve Months) | -474.77% |
| Return on Assets (5 Year) | -755.77% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -1,046.97% |
| Return on Equity (Trailing Twelve Months) | -975.04% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -915.89% |
| Return on Investment (Trailing Twelve Months) | -781.78% |
| Return on Investment (5 Year) | -99,999.99% |